Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK plc has repurchased 550,000 ordinary shares on 4 March 2026 through BNP Paribas as part of its ongoing share buyback programme, paying a volume-weighted average price of 2,129.91 pence per share. The shares, with prices ranging between 2,109 and 2,149 pence across London and Cboe venues, will be held in treasury rather than cancelled.
Following this latest transaction, GSK’s treasury stock has risen to 245,707,094 shares, while 4,070,455,394 shares remain in issue and carry voting rights. Treasury holdings now represent 6.04% of total voting rights, information the company highlighted as relevant for investors monitoring disclosure thresholds under UK transparency rules.
The buyback, in place since mid-February and now totaling 5,816,000 shares repurchased, underscores GSK’s continued use of share repurchases as a capital-allocation tool. By concentrating voting rights among remaining shareholders and signaling confidence in its valuation, the programme may modestly enhance earnings per share and underlines the group’s focus on shareholder returns alongside its core biopharmaceutical operations.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing, manufacturing and marketing vaccines and specialty and general medicines. The group targets major therapeutic areas including infectious diseases, HIV, respiratory conditions and oncology, and is a constituent of the UK blue-chip indices with a broad international shareholder base.
As one of the largest listed healthcare groups in Europe, GSK actively manages its capital structure through dividends and share repurchases. The company’s scale, diversified portfolio and recurring cash flows underpin a longstanding commitment to shareholder returns while funding research and development to sustain its competitive position in the pharmaceuticals and vaccines markets.
Average Trading Volume: 8,962,046
Technical Sentiment Signal: Buy
Current Market Cap: £85.07B
Learn more about GSK stock on TipRanks’ Stock Analysis page.